 SOUTH PLAINFIELD, N.J., March 16, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today announced two-year data from Part 2 of the SUNFISH trial evaluating EvrysdiTM risdiplam in children and adults with Type 2 or Type 3 spinal muscular atrophy SMA at the 2021 Muscular Dystrophy Association MDA Virtual and Scientific Conference. 